An official website of the United States government
Home
Name
Afinitor
Alternate Names
Afinitor
Certican
Everolimus
RAD001
Abbreviations
None
Category
Chemotherapy
Subcategory
Cytostatic agent--antiangiogenesis agent and mTOR inhibitor
NSC Number
733504
Primary Site
Histology
None
Remarks
April 10, 2018: FDA approved everolimus tablets for oral suspension (Afinitor) for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Everolimus is also approved for two other manifestations of TSC: TSC-associated subependymal giant cell astrocytoma (SEGA) and TSC-associated renal angiomyolipoma
March 2009/April 2010/May 2011:Everolimus has received FDA approval for treatment of advanced kidney cancer, subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) in patients who are not suitable for surgical intervention. April 2010, progressive or metastatic pancreatic neuroendocrine tumors not surgically removable (May 2011).
February 26, 2016: FDA approved everolimus for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of GI or lung origin with unresectable, locally advanced or metastatic disease.
March 2009/April 2010/May 2011:Everolimus has received FDA approval for treatment of advanced kidney cancer, subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) in patients who are not suitable for surgical intervention. April 2010, progressive or metastatic pancreatic neuroendocrine tumors not surgically removable (May 2011).
February 26, 2016: FDA approved everolimus for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of GI or lung origin with unresectable, locally advanced or metastatic disease.
Coding
This drug should be coded
